Answers are grounded in this paper and cite their sources.
Demonstrates Mcl-1 PROTAC efficacy in degrading anti-apoptotic proteins in chemoresistant ovarian cancer, suggesting improved therapeutic options.
Evasion of apoptosis is a hallmark of tumor progression, often driven by the overexpression of anti-apoptotic proteins from the Bcl-2 family, including Mcl-1. Mcl-1 has emerged as a critical therapeutic target, particularly in chemoresistant cancers such as ovarian cancers. This anti-apoptotic protein has been involved not only in the resistance to various conventional chemotherapeutic agents, but also in the resistance to BH3-mimetic molecules targeting Bcl-2 and/or Bcl-x L proteins, leading in some cases to therapeutic failures of these innovative molecules. However, conventional Mcl-1 inhibitors are hindered by off-target effects and toxicity, especially cardiac toxicity. To address these limitations, we have designed a PROTAC targeting Mcl-1, derived from the repositioning of an oligopyridine-based inhibitor. Its efficacy was evaluated in the IGROV1-R10 ovarian cancer cell line, a chemoresistant model. Our results demonstrate 80-90% Mcl-1 degradation after 48 hours at 10 nM, as confirmed by western blot analysis. Furthermore, a comprehensive study of its physicochemical properties and pharmacokinetic parameters allowed us to characterize its entire cellular journey, from membrane permeability to ternary complex formation with the CRBN E3 ligase. This integrated approach highlights the challenges associated with PROTACs and proposes new optimization strategies to enhance their efficacy and selectivity. This work contributes to the development of targeted degradation strategies to overcome chemoresistance and paves the way for innovative anticancer therapies. • Potent and selective Mcl-1 PROTAC designed via structure-based optimization • Up to 80% Mcl-1 degradation at 10 nM after 48 hours in ovarian cancer cells. • Comprehensive physicochemical profiling was performed both in vitro and in silico. • Ternary complex formation with CRBN E3 ligase was validated in vitro and in silico. • Study advances Mcl-1 PROTAC design for treating chemoresistant cancers.
No takes yet. Share an insight, caveat, or question.
Cornu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: